重组活化因子Ⅶ的研究进展
Investigative Progress of Recombinant Activating Factor Ⅶ
出处
《诊断学理论与实践》
2002年第4期275-276,共2页
Journal of Diagnostics Concepts & Practice
参考文献11
-
1[1]Bouma BN, Miejers JC.Fibrinolysis and the contact system:a role for factorⅪ in the down-regulation of fibrinolysis[J].Thromb Haemost, 1999,82(2):243-250.
-
2[2]Monroe DM,Hoffman M,Oliver JA,et al. Platelet activity of high-dose factor Ⅶa is independent of tissue factor [J].Br J Haematol, 1997,99(3):542-547.
-
3[3]Lisman T, Nieuwenhuis HK,Meihers JCM,et al. Recombinant factor Ⅶ a prevents premature fibrinolysis in plasma of some but not all patients with sever haemophilia A(abstract) [J].Thromb Haemost, 1999,(Suppl 1):504.
-
4[4]Shapiro AD, Gilchrist GS, Hoots WK, et al. Prospective randomised trial of two doses of rFⅦa (Novo Seven)in haemophilia patients with inhibitors undergoing surgery.Thromb Haemost, 1998 , 80(5):773-778.
-
5[5]Key NS,Aledort LM,Beardsley D,et al. Home treatment of mild to morderate bleeding episodes using recombinant factor Ⅶa (Novoseven) in haemophiliacs with inhibitors[J].Thromb Haemost, 1998 , 80(6):912-918.
-
6[6]Cooper HA,Jones CP, Campion E, et al. Successful use of high dose rF Ⅶ a in a high titer inhibitor patient with hemophilia B during major orthopedic manipulations and rehabilitation to release fixed flexion contractions of both knees(abstract).Haemophilia,2000,6:297.
-
7[7]Kristensen J,Killander A,Hippe E,et al. Clinical experience with recombinant factor Ⅶ a in patients with thrombocytopenia[J].Haemostasis, 1996,26(Suppl 1):159-164.
-
8[8]Kenet G, Walden R, Eldad A,et al. Treatment of traumatic bleeding with recombinant factor Ⅶa[J].Lancet, 1999,354:1879.
-
9[9]Martinowitz U, Holcomb JB,Pusateri AE,et al. Intravenous rFⅦa administered for hemorrhage control in hypothermic coagulopathic swine with grade Vliver injuries[J].J Trauma,2001,50(4):721-729.
-
10[10]Mariani G,Teata MG,Di Paolantonio T,et al. Use of recombinant, activated factor Ⅶ in the treatment of congenital factor Ⅶ deficiencies[J].Vox Sang, 1999 , 77(3):131-136.
-
1沈志祥,陈昀.重组活化因子Ⅶ的临床应用进展[J].国外医学（输血及血液学分册）,2003,26(4):332-335. 被引量：2
-
2Louis M.Aledort,张海燕.超说明书使用重组活化因子Ⅶ需警惕安全性[J].中国处方药,2010,9(11).
-
3李宏建.重组活化因子Ⅶ治疗急性脑出血[J].国外医学（脑血管疾病分册）,2005,13(3):239-239. 被引量：1
-
4周洁民,侯国英,胡以平,邱信芳,薛京伦.Ⅸ因子重组质粒的构建及其转化细胞移植在小鼠体内的表达[J].科学通报,1992,37(16):1513-1516. 被引量：3
-
5李宏建.重组活化因子Ⅶ治疗急性脑出血的疗效和安全性[J].国际脑血管病杂志,2008,16(12):934-934. 被引量：4
-
6Mojca Remskar Konia.重组活化因子Ⅶ在心脏手术中的应用:抑肽酶之后的新型药物(英文)[J].临床麻醉学杂志,2012,28(1):98-101. 被引量：1
-
7刘敬忠,陈怀华,张纪平,尹洪臣,曾淑燕,石奇珍,王海燕,Erica Vielhaber,Steve S.Sommer.27例乙型血友病患者Ⅸ因子基因突变研究[J].高技术通讯,1994,4(8):29-32. 被引量：3
-
8罗峰,秦世真,蒋左庶,邱信芳,薛京伦.50例中国人IX因子基因的限制性片段长度多态性[J].复旦学报（自然科学版）,1990,29(1):114-118.
-
9戴一凡,邱信芳,薛京伦,刘祖洞.带有人Ⅸ因子cDNA的反转录病毒载体的构建及其在血友病B患者皮肤成纤维细胞中的高效转移和表达[J].中国科学（B辑）,1990(12):1284-1292. 被引量：8
-
10李宏建.NiaStase(rFⅦa)有望作为有效治疗脑出血的首选药[J].国外医学（脑血管疾病分册）,2004,12(8):575-575.
